PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026JCEM Case Reports0 citationsOpen Access

P-048 Mody 8 Due to Cel Gene Mutation in a 41-Year-Old Female: A Diagnostic Challenge and Management Update

View Full Paper
SNSuha Adil NasirSYSeif Eldein YahiaVEVinay Eligar

Key Points

  • This case explores the diagnosis and management of a 41-year-old female with MODY type 8 due to a CEL gene mutation.
  • Clinical assessment of a 41-year-old female with atypical diabetes symptoms.
  • Genetic testing identified a CEL mutation and an incidental WFS1 mutation.
  • Management transitioned from insulin to Tirzepatide, Metformin, and SGLT2 inhibitors.
  • Improvement in HbA1c from high levels to 7.6%.
  • BMI reduction from 26.1 kg/m² to 22.94 kg/m² after treatment change.
  • Identification of the CEL mutation led to personalized therapy.

Abstract

Abstract Introduction Maturity-Onset diabetes of the Young (MODY) is a monogenic form of diabetes often mimicking Type 1 or Type 2 diabetes MODY type 8 (MODY 8), resulting from mutations in the CEL gene, is rare and associated with pancreatic exocrine dysfunction and hepatic abnormalities. Clinical Case A 41-year-old female, BMI 26.1 kg/m², diagnosed with diabetes at age 16, had persistent hyperglycemia despite insulin therapy. Her phenotype was atypical for Type 1 or 2 diabetes, exhibiting adequate C-peptide levels, negative autoimmune markers, hyperlipidemia, hepatic steatosis, elevated transaminases, and vitamin D deficiency. Genetic testing identified a CEL mutation (c.1843del, p. Ala615Profs92), heterozygous and likely pathogenic. An incidental WFS1 mutation (c.2600GA, p. Trp867) was also found. Identification of the CEL mutation prompted a shift from insulin to Tirzepatide, Metformin, and SGLT2 inhibitors. Follow-up showed improvement in HbA1c to 7.6% and BMI to 22.94 kg/m². Conclusion Clinicians should consider MODY in non-obese, early-onset diabetic patients lacking autoimmune markers. Genetic testing facilitates precision diagnosis, personalized therapy, and reduces unnecessary insulin use.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nasir et al. (2026) studied this question.

synapsesocial.com/papers/6967195987ba607552bb94d1https://doi.org/10.1210/jcemcr/luaf297.040
Ask AI
Helpful
Bookmark
Share
View Full Paper